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 This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated pro-
drug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytope-
nia was observed.
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A 41 years old male patient with squamous carcinoma 
of the tongue (T2N0M0) refused any adjuvant chemo-
therapy after the surgery. He developed lung metastases 
9 months after the second surgery for local relapse. 
After an approval of the Ministry of Health of the Slovak 
Republic, on day −2 he was admitted to the hospital. 
Infusion of Ancotil (2.5 g flucytosine/250 ml solution) 
started on day −1 bid 24 hours before the administration 
of therapeutic stem cells (TSC), and continued for 7 days. 
On day 0 the patient received 60×106 allogenic TSC 
intravenously. The therapeutic adipose tissue-derived 
mesenchymal stem cells were prepared as described 
previously [1]. There were no adverse effects during and 
6 h after the administration. 18 hours after the intravenous 
administration of the TSC, the patient developed fever 
(39.0 °C) with no signs of circulation instability. The fever 
resolved after antipyretics. There were no signs of any mi-
crobial infection. The following days the patient remained 
afebrile. Due to a sudden drop of white blood cells he re-
ceived an oral antibacterial and antimycotic prophylaxis. 
On the day +6 he was discharged from the hospital with 
almost normalized blood counts. On day +18 during the 
outpatient control he was doing well. His blood counts 
(except mild anemia) were normal (Table). The CT scan 
performed on day +6 showed no difference in the size 
or density of his pulmonary metastases compared to the 
CT scan on day −1. On the day +40 there were signs 
of a progression of the metastases on the CT scan. 
Table. Blood counts of the patient during and after the therapy
Day Leukocytes (×10-12/l)
Neutrophils 
(×10-12/l)
Erythrocytes 
(×10-15/l) Hb (g/l)
Plt 
(×10-14/l)
–2 6.88 4.86 4.41 134 179
0 5.82 3.98 3.71 119 150
+1 4.06 3.41 3.80 119 119
+2 1.99 1.00 3.41 112 100
+3 2.89 1.58 3.72 117 115
+4 3.50 2.16 3.72 115 122
+5 4.50 2.98 3.79 118 129
+6 4.29 2.63 3.89 121 132
+18 6.57 4.66 4.06 125 191
The treatment with TSC of this patient highlighted two 
points: 1) There was no sign of any therapeutic effect after 
intravenous (not local, i.e. intratumoral) administration 
of the TSC. 6 days after the administration the metastatic 
process did not show any signs of regression. Moreover, 
after 40 days after the treatment there was a progression 
of the metastases. 2) After the intravenous administra-
tion the TSC are pro bably “homing” in the bone marrow 
despite the adipose tissue origin. Even a rather low cell 
count (60•106) was able to cause grade 2 (3) thrombope-
nia (neutropenia). It should be noted that this patient did 
not receive any systemic chemotherapy in the past. The 
observed bicytopenia with a nadir occurred 48 h after the 
administration of TSC (with concomitant prodrug adminis-
tration). Therefore it should be carefully considered when 
a medical team decides to use the intravenous route. 
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